- Ian Cree, University Hospitals Coventry and Warwickshire
- John A Hartley, University College London
- Manami Inoue, University of Tokyo
- Ferdinando Mannello, University Carlo Bo of Urbino
- Christophe Nicot, Kansas University Medical Center
- Stephen P Povoski, The Ohio State University
- Charles Rosser, University of Hawaii Cancer Center
- Dirk Vordermark, Martin Luther University Halle-Wittenberg
- Dafne Solera, BioMed Central
Tumor-induced downregulation of Connexin 43, a component of Gap Junctions and regulator of vessel quiescence, frees endothelium to respond to angiogenic cues and may be an imprortant mechanism of tumor vascularization.
The levels of four urinary miRNAs that are specifically altered in breast cancer patients compared to healthy controls may serve as potential non-invasive innovative biomarkers to detect primary breast cancer.
A novel high-throughput screening method for public cancer signature validation identifies two robust signatures that differentiate TP53 mutation status and have prognostic and predictive value for breast cancer patients.
Nicola Normanno and Ian Cree comment on the role of genomics in oncology, and the issues to overcome before targeted treatment based on genomic profile can become routinely accessible to lung cancer patients.
Cancers of unknown primary origin (CUP) exhibit distinct molecular features compared to metastases of known origin and display signatures of chromosome instability which may account for their uncommon clinical presentation and poor outcome.
A higher maximum of standardized uptake value (SUVmax) on 18F-FDG PET is associated with elevated tumor levels of pAkt and pS6 protein and with aggressive behavior and metastatic potential of renal cell carcinoma (RCC).
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
BMC Cancer is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
BMC series - open, inclusive and trusted.
- Cell and molecular biology
- Epidemiology, prevention and public health
- Experimental therapeutics and drug development
- Genetics, genomics and epigenetics
- Infection, immunity and cancer vaccines
- Medical and radiation oncology
- Surgical oncology, cancer imaging, and interventional therapeutics
- Systems biology, post-genomic analysis and emerging technologies
- Translational oncology
Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1BMC Cancer 2013, 13:14 (10 January 2013)
BMC series blog
- 01 September 2015
- The oldest and the scariest sea scorpion: a giant discovery
- 27 August 2015
- Improving rice for the future: an author Q+A
- 26 August 2015
- Studying the world’s rarest ape: insights from the field